InspireMD announced that the FDA has approved its Investigational Device Exemption (IDE) application to start the CGUARDIANS III pivotal study for the SwitchGuard neuro protection system. This system, used with the CGuard Prime 80 cm stent, aims to improve stroke prevention during transcarotid artery revascularization (TCAR) procedures. The study is led by experienced vascular surgeons and targets a U.S. commercial launch in 2027, pending approval. This marks a significant step for InspireMD in advancing its carotid stent technology and expanding its stroke prevention tools.
Nexans and Hydro have agreed on a five-year contract for about 85,000 tonnes of low-carbon aluminium wire rod to support Europe's electricity grid modernization. This aluminium, produced using 100% renewable energy in Norway, will help reduce carbon ...
Nexans and Hydro have agreed on a five-year supply contract for about 85,000 tons of low-carbon aluminum wire rod to support the modernization and decarbonization of Europe's electrical grid. The aluminum, produced in Norway using 100% renewable ener...
Scilex Holding Company announced a binding term sheet with Kazakhstan-based iHolding Group LLP for a $100 million investment, purchasing about 6.67 million shares at $15 each. This funding aims to support Scilex's strategic growth in healthcare, prod...
Following Shell's interim dividend payment for Q1 2026 on June 29, several senior executives, including CEO Wael Sawan and CFO Sinead Gorman, acquired shares through dividend reinvestment plans. These shares were obtained in respect of shares previou...
The global aliphatic hydrocarbon solvents and thinners market is projected to grow from $5.26 billion in 2026 to $6.81 billion by 2032, at a CAGR of 4.4%. Growth is fueled by rising demand in coatings, adhesives, and industrial maintenance, with mine...
